DexCom Inc (DXCM) stock
Close on Nov 12, 2026Market cap $30.35BP/E 32.0Yield –
DexCom Inc grew revenue 13.0% to $5.10B over the twelve months to Sep 30, 2026. Operating income rose 57.4% to $1.22B, moving the operating margin from 17.2% to 24.0%. Free cash flow was $1.10B, up 3.4% from a year earlier. At the latest close the market valued the company at $30.35B, 32.0 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $30.35B
- P/E ratio
- 32.0
- Price to sales
- 5.95
- Price to book
- 11.97
- Dividend yield
- –
- Free cash flow yield
- 3.62%
Fundamentals
- Revenue
- $5.10B
- Net income
- $991.00M
- EPS, diluted
- $2.54
- Free cash flow
- $1.10B
- Book value per share
- $6.61
- Diluted shares
- 384M
Trading
- Next earnings
- Feb 11, 2027 (estimated, after the close)
- Previous close
- $80.34
- Open
- $80.99
- Day's range
- $79.38 – $82.51
- Volume
- 4,087,159
- Average volume (20 days)
- 5,026,628
- Index membership
- S&P 500 (since Jun 2020), Nasdaq-100, Russell 1000, Russell 3000
- Beta (5 years)
- 1.19
- 52-week range
- $56.72 – $92.59
- RSI (14 days)
- 47.4
- Volatility (1 year)
- 37.9%
- Relative volume
- 0.90×
- WACC
- 10.8%
On 3 of our idea lists: Undervalued and financially sound, Top scores, Buyback cannibals
Index membership is inferred from the holdings of funds that track each index (VOO, IVV, SPYM, QQQ, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | DXCM | S&P 500 | Difference | DXCM per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -5.3% | -2.7% | −2.6 pts | ||
| 3 months | -10.4% | -1.7% | −8.6 pts | ||
| Year to date | +22.6% | +11.9% | +10.7 pts | ||
| 1 year | +36.5% | +12.0% | +24.6 pts | ||
| 3 years | -13.5% | +78.2% | −91.6 pts | -4.7% | +21.2% |
| 5 years | -49.6% | +73.2% | −122.9 pts | -12.8% | +11.6% |
| 10 years | +399.5% | +309.6% | +89.8 pts | +17.4% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases DexCom filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- Results
- Update
About DexCom
Surgical & Medical Instruments & Apparatus
DexCom, Inc. is a medical device company focused on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for diabetes management and metabolic health. Its core product lineup features wearable sensor systems, including the Dexcom G7, G7 15 Day, and Dexcom ONE+, which continuously track glucose levels and wirelessly transmit readings and alerts to compatible receivers, mobile applications, and connected insulin delivery devices. The company also offers Stelo, an over-the-counter glucose biosensor designed for adults with prediabetes or non-insulin-treated Type 2 diabetes. Its customer base primarily comprises individuals with Type 1 and Type 2 diabetes, their caregivers, healthcare professionals, and health-conscious adults seeking to track glucose trends.
Company profile, executives and historyDexCom stock: common questions
What is DexCom's stock price?
DXCM closed at $81.39 on Nov 12, 2026, up 1.30% on the day. Over the past 52 weeks it traded between $56.72 and $92.59.
What is DexCom's market cap?
DexCom was worth $30.35B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is DXCM's P/E ratio?
DXCM trades at 32.0 times earnings, based on diluted earnings per share of $2.54 over the twelve months to Sep 30, 2026.
How much revenue does DexCom make?
DexCom reported revenue of $5.10B for the twelve months to Sep 30, 2026, up 13.0% from a year earlier.
Does DexCom pay a dividend?
No. DexCom has not paid a cash dividend over the last twelve months.
When does DexCom report earnings next?
DexCom is expected to report Q4 FY2026 results on Feb 11, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has DXCM stock performed over the past year?
Including dividends, DXCM returned +36.5% over the past year, against +12.0% for the S&P 500.
How many DXCM shares are sold short?
16M shares were sold short at the latest FINRA report, 4.29% of the float, or 2.8 days of average trading volume.
Who are DexCom's competitors?
Companies most similar to DexCom by business, industry and size include MMED, PODD, TNDM, RMD, TFX.
See a number that looks wrong?